Form 4: Tandem Diabetes COO's Stock Vesting & Tax Withholding

Tandem Diabetes Care Inc.'s EVP & COO, Jean-Claude Kyrillos, reported the vesting of 3,636 restricted stock units and the withholding of 2,118 shares for tax obligations.

Summary

• Jean-Claude Kyrillos, Executive Vice President & Chief Operating Officer of Tandem Diabetes Care Inc. (TNDM), reported transactions on January 15, 2026.
• Kyrillos acquired 3,636 shares of common stock through the vesting of restricted stock units (RSUs) at a price of $0.
• Concurrently, 2,118 shares of common stock were disposed of at a price of $21.07 to satisfy tax withholding requirements related to the RSU vesting.
• Following these transactions, Kyrillos beneficially owns 24,062 shares of common stock directly.
• Kyrillos also holds 21,817 derivative securities in the form of Restricted Stock Units.
• The RSUs were awarded on July 15, 2024, under the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan.
• The vesting schedule for these RSUs includes 33% on July 15, 2025, with the remainder vesting in eight equal quarterly installments thereafter.

Sentiment

Score: 5

Explanation: The filing reports a routine executive compensation event (RSU vesting and tax withholding) which is neutral in sentiment. It reflects standard corporate governance and compensation practices without indicating any unexpected positive or negative developments for the company.

Positives

• The vesting of 3,636 restricted stock units represents a component of executive compensation, indicating continued alignment of management interests with shareholder value.

Negatives

• 2,118 shares were withheld by the company to cover tax obligations arising from the RSU vesting, which slightly reduces the direct shareholding.

Future Outlook

The filing indicates future vesting events for the remaining Restricted Stock Units, with installments continuing quarterly after July 15, 2025.

Industry Context

This Form 4 filing is a routine disclosure of an executive's compensation-related stock transactions and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The report reflects a routine compensation event for a key executive, aligning management incentives with shareholder interests through equity ownership. The tax withholding is a standard practice and not a discretionary sale.
• Employees: This filing pertains to executive compensation and does not directly impact the broader employee base.

Next Steps

• Remaining Restricted Stock Units will vest in eight equal quarterly installments following the initial 33% vesting on July 15, 2025.

Key Dates

Keywords

TNDM, Tandem Diabetes Care, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Ownership